Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis
Authors:
Open Access
- 6 June 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1404191
Abstract
Myasthenia Gravis (MG) is a chronic disabling autoimmune disease caused by autoantibodies to the neuromuscular junction (NMJ), characterized clinically by fluctuating weakness and early fatigability of ocular, skeletal and bulbar muscles. Despite being commonly considered a prototypic autoimmune disorder, MG is a complex and heterogeneous condition, presenting with variable clinical phenotypes, likely due to distinct pathophysiological settings related with different immunoreactivities, symptoms’ distribution, disease severity, age at onset, thymic histopathology and response to therapies. Current treatment of MG based on international consensus guidelines allows to effectively control symptoms, but most patients do not reach complete stable remission and require life-long immunosuppressive (IS) therapies. Moreover, a proportion of them is refractory to conventional IS treatment, highlighting the need for more specific and tailored strategies. Precision medicine is a new frontier of medicine that promises to greatly increase therapeutic success in several diseases, including autoimmune conditions. In MG, B cell activation, antibody recycling and NMJ damage by the complement system are crucial mechanisms, and their targeting by innovative biological drugs has been proven to be effective and safe in clinical trials. The switch from conventional IS to novel precision medicine approaches based on these drugs could prospectively and significantly improve MG care. In this review, we provide an overview of key immunopathogenetic processes underlying MG, and discuss on emerging biological drugs targeting them. We also discuss on future direction of research to address the need for patients’ stratification in endotypes according with genetic and molecular biomarkers for successful clinical decision making within precision medicine workflow.Keywords
This publication has 134 references indexed in Scilit:
- Batoclimab vs Placebo for Generalized Myasthenia GravisJAMA Neurology, 2024
- Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extensionAnnals of Clinical and Translational Neurology, 2023
- Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia GravisJAMA Neurology, 2022
- Consistent improvement with eculizumab across muscle groups in myasthenia gravisAnnals of Clinical and Translational Neurology, 2020
- Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell TransplantationJAMA Neurology, 2016
- Interleukin‐10 producing‐B cells and their association with responsiveness to rituximab in myasthenia gravisMuscle & Nerve, 2013
- Epstein‐Barr virus persistence and reactivation in myasthenia gravis thymusAnnals of Neurology, 2010
- CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myastheniaAnnals of Neurology, 2009
- Correlation of C3 level with severity of generalized myasthenia gravisMuscle & Nerve, 2009
- Novel complement inhibitor limits severity of experimentally myasthenia gravisAnnals of Neurology, 2009